- Home
- SYY vs ARGX Comparison
SYY vs ARGX Comparison
Compare SYY & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYY
- ARGX
- Stock Information
- Founded
- SYY 1969
- ARGX 2008
- Country
- SYY United States
- ARGX Netherlands
- Employees
- SYY N/A
- ARGX N/A
- Industry
- SYY Food Distributors
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYY Consumer Discretionary
- ARGX Health Care
- Exchange
- SYY Nasdaq
- ARGX Nasdaq
- Market Cap
- SYY 37.9B
- ARGX 35.2B
- IPO Year
- SYY N/A
- ARGX 2017
- Fundamental
- Price
- SYY $79.52
- ARGX $606.47
- Analyst Decision
- SYY Strong Buy
- ARGX Strong Buy
- Analyst Count
- SYY 14
- ARGX 21
- Target Price
- SYY $85.50
- ARGX $619.79
- AVG Volume (30 Days)
- SYY 2.7M
- ARGX 314.5K
- Earning Date
- SYY 10-29-2024
- ARGX 10-31-2024
- Dividend Yield
- SYY 2.57%
- ARGX N/A
- EPS Growth
- SYY 9.58
- ARGX N/A
- EPS
- SYY 3.89
- ARGX N/A
- Revenue
- SYY $79,708,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- SYY $5.32
- ARGX $61.99
- Revenue Next Year
- SYY $4.31
- ARGX $42.48
- P/E Ratio
- SYY $20.44
- ARGX N/A
- Revenue Growth
- SYY 3.76
- ARGX 85.56
- 52 Week Low
- SYY $69.03
- ARGX $327.73
- 52 Week High
- SYY $82.89
- ARGX $622.32
- Technical
- Relative Strength Index (RSI)
- SYY 64.86
- ARGX 59.06
- Support Level
- SYY $75.57
- ARGX $601.64
- Resistance Level
- SYY $77.36
- ARGX $622.32
- Average True Range (ATR)
- SYY 1.39
- ARGX 11.91
- MACD
- SYY 0.30
- ARGX 0.77
- Stochastic Oscillator
- SYY 99.04
- ARGX 75.30
About SYY Sysco Corporation
Sysco is the largest US foodservice distributor with 17% share of the highly fragmented $370 billion domestic market. It distributes roughly 500,000 food and nonfood products to restaurants (62% of fiscal 2024 revenue), education and government buildings (7%), travel and leisure (6%), healthcare facilities (7%), and other locations (18%) where individuals consume away-from-home meals. In fiscal 2024, 70% of the firm's revenue was derived from its US foodservice operations, while its international (18%), quick-service logistics (10%), and other (2%) segments contributed the rest.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.